Abstract
Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) MICs were evaluated for a collection of 309 beta-lactam-resistant isolates of Pseudomonas aeruginosa recovered from three institutions in the area of Los Angeles, CA. Overall, 12.0% of isolates were susceptible to imipenem, 15.9% were susceptible to meropenem, 20.7% were susceptible to piperacillin-tazobactam, 24.6% were susceptible to ceftazidime, 25.9% were susceptible to cefepime, 72.5% were susceptible to C/T, and 61.8% were susceptible to CZA. Among C/T-resistant isolates, 9.1% were CZA susceptible, whereas 36.4% of CZA-resistant isolates were susceptible to C/T.
Keywords:
MIC; Pseudomonas aeruginosa; ceftazidime-avibactam; ceftolozane-tazobactam; susceptibility testing.
Copyright © 2017 American Society for Microbiology.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Azabicyclo Compounds / pharmacology*
-
Cefepime
-
Ceftazidime / pharmacology*
-
Cephalosporins / pharmacology*
-
Drug Combinations
-
Gene Expression
-
Humans
-
Los Angeles
-
Meropenem
-
Microbial Sensitivity Tests
-
Penicillanic Acid / analogs & derivatives*
-
Penicillanic Acid / pharmacology
-
Piperacillin / pharmacology
-
Piperacillin, Tazobactam Drug Combination
-
Pseudomonas Infections / drug therapy
-
Pseudomonas Infections / microbiology
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / enzymology
-
Pseudomonas aeruginosa / genetics
-
Pseudomonas aeruginosa / isolation & purification
-
Tazobactam
-
Thienamycins / pharmacology
-
beta-Lactam Resistance / genetics*
-
beta-Lactamases / genetics*
-
beta-Lactamases / metabolism
Substances
-
Anti-Bacterial Agents
-
Azabicyclo Compounds
-
Cephalosporins
-
Drug Combinations
-
Thienamycins
-
avibactam, ceftazidime drug combination
-
ceftolozane, tazobactam drug combination
-
Piperacillin, Tazobactam Drug Combination
-
Cefepime
-
Penicillanic Acid
-
Ceftazidime
-
beta-Lactamases
-
Meropenem
-
Tazobactam
-
Piperacillin